scPharmaceuticals was founded to accelerate the evolution of infused therapies by bringing the advantages of outpatient care with subcutaneous drug delivery to the treatment of medical conditions that would otherwise require intravenous infusion in a clinical setting.

Our lead program, subcutaneous furosemide for diuresis in heart failure, and our follow-on programs focused on select anti-infective agents, have the potential to effectively treat millions of patients in the comfort of their own homes and at a reduced cost of care.

Through the ongoing development and application of our proprietary subcutaneous formulations and delivery technologies to these critical care medicines, we seek to liberate more patients, caregivers, practitioners, and payers from the costs and constraints of inpatient care.